Phoenix Rising Adds Two New Board Members
Mark Berry introduces the new President of Phoenix Rising, Dr. Gary Solomon, and welcomes Professor Jonathan Edwards to the Phoenix Rising Board of Directors.
Discuss the article on the Forums.

Prof Jonathon Edwards to be IiME Rituximab trial advisor

Discussion in 'General ME/CFS News' started by Sasha, Jul 14, 2013.

  1. Sasha

    Sasha Fine, thank you

    Messages:
    9,572
    Likes:
    10,044
    UK
    Bob, Esther12, Sean and 4 others like this.
  2. Purple

    Purple Bundle of purpliness

    Messages:
    1,419
    Likes:
    2,403
    EXCELLENT NEWS!
    (yes, I did mean to shout this...)
     
    SOC, Dolphin, sproggle and 1 other person like this.
  3. user9876

    user9876 Senior Member

    Messages:
    905
    Likes:
    2,390
    sproggle, SOC, Esther12 and 2 others like this.
  4. Esther12

    Esther12 Senior Member

    Messages:
    5,588
    Likes:
    6,669
    Good news.

    Hopefully he might be able to advance work on finding a way of identifying those patients most likely to benefit. Linking the rituximab CFS work to others working in a similar area but outside of CFS seems like a really positive move.
     
    Sasha and Valentijn like this.
  5. Gemini

    Gemini Senior Member

    Messages:
    410
    Likes:
    357
    Esther,

    You're absolutely right!

    In RA they can identify non-responders to rituximab using an interferon [gene expression] signature:

    "The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients, " Arthritis Res Ther, April 2012

    http://www.ncbi.nlm.nih.gov/pubmed/22540992

    Let's hope the Professor is familiar with this groundbreaking work in another disease & can apply it to ME/CFS.
     
    Sasha and Valentijn like this.

See more popular forum discussions.

Share This Page